FIELD: biotechnology.
SUBSTANCE: bone-targeted antibody containing a heavy chain and a light chain that specifically binds to TGFβ1, TGFβ2 and TGFβ3 is suggested. The antibody is modified with one or more polyaspartic acid peptides to improve the localization of the antibody in the bone. Also the methods of making and using the said antibody to treat a human with bone disease are disclosed.
EFFECT: invention provides improved efficacy in the treatment of pathophysiological bone degeneration while minimizing potential adverse side effects.
22 cl, 47 dwg, 11 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| MUTANT VARIANTS OF Fc IgG1 DEVOID OF EFFECTOR FUNCTIONS | 2018 |
|
RU2764559C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| MOLECULES BINDING MESOTHELIN AND CD137 | 2019 |
|
RU2815066C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
